TY - JOUR T1 - Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer JF - In Vivo JO - In Vivo SP - 1035 LP - 1039 VL - 31 IS - 5 AU - TOSHIYA MAEKURA AU - MAIKO NAITO AU - MASAHIRO TAHARA AU - NAOYA IKEGAMI AU - YOHEI KIMURA AU - SHOKO SONOBE AU - TAKEHIKO KOBAYASHI AU - TAISUKE TSUJI AU - SHOJIRO MINOMO AU - AKIHIRO TAMIYA AU - SHINJI ATAGI Y1 - 2017/09/01 UR - http://iv.iiarjournals.org/content/31/5/1035.abstract N2 - Background/Aim: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. Patients and Methods: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed. Results: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism. Conclusion: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism. ER -